

**Table 1.** Different breeding types observed in *N. nimmoniana*

Flower types borne by the individual plants	Breeding types at individual level	Occurrence (%) <i>n</i> = 60
Only male flowers	Male	10
Only female flowers	Female	34
Male and female flowers	Monoecious	2
Only bisexual flowers	Hermaphrodite	12
Male flowers with few bisexual flowers	Andromonoecious	30
Female flowers with few bisexual flowers	Gynomonoecious	5
Mixture of male, female and bisexual flowers	Trimonoecious	7

**Table 2.** Variation of floral traits in *N. nimmoniana*

Character	Bisexual flower mean $\pm$ S.D	Male flower mean $\pm$ S.D.	Female flower mean $\pm$ S.D.
Flower diameter (mm)	7.2 $\pm$ 0.02	9.4 $\pm$ 0.05	6.90 $\pm$ 0.02
Flower length (mm)	7.4 $\pm$ 0.15	9.2 $\pm$ 0.31	6.2 $\pm$ 0.10
Petal length (mm)	6.5 $\pm$ 0.16	7.9 $\pm$ 0.02	5.60 $\pm$ 0.20
Petal width (mm)	2.4 $\pm$ 0.20	2.8 $\pm$ 0.24	2.00 $\pm$ 0.13
Length of anther filament (mm)	3.0 $\pm$ 0.13	6.8 $\pm$ 0.24	2.04 $\pm$ 0.07
Length of gynoecium (mm)	5.0 $\pm$ 0.25	3.5 $\pm$ 0.31	5.70 $\pm$ 0.40
No. of petals	Four or five	Five	Five
No. of functional anthers	1–2	All	None
Stigma	Active	Rudimentary	Active

Mean of 25 flowers collected from at least five individuals of each breeding type.

ish in colour and with rudimentary stamens that produce no pollen grains. The pistils are 5.7 mm in length. Anthesis of female flowers occurs during early morning (0600–0800 h). Longevity of female flowers varies from two to eight days depending upon their pollination.

Bisexual flowers are intermediate to male and female flowers in size. They are 7.4 mm in length, 7.2 mm in diameter and are dull yellow in colour. Both stamens and pistils are medium in size and are 3.0 mm and 5.0 mm in length respectively. In bisexual flowers, only 1–2 anthers produce pollen grains and stigma is active.

Flowering begins during July to August and most of the early flowering trees are dioecious, whereas late flowering trees are monoecious, hermaphrodite and a mixture of other breeding types. The flowers open mostly on sunny days. The number of flowers per inflorescence in male, female and bisexual plants varies greatly. Male inflorescence carries relatively higher number of flowers (350–530) than those bearing female flowers alone (70–185) and bisexual flowers (90–210). Further, the production of lesser number of flowers per inflorescence in bisexual trees and female trees might be a device to save energy for

fruit production, whereas higher number of flowers per inflorescence among male trees may help in pollinator attraction and pollen movement between female and male trees.

- Govindachari, T. R. and Viswanathan, N., *Phytochemistry*, 1972, **11**, 3529–3531.
- Wall, M. E., Wani, M. C., Cook, C. E., Palmer, K. H., Mcphail, A. T. and Sim, G. A., *J. Am. Chem. Soc.*, 1966, **88**, 3888–3890.
- Creemers, G. J. *et al.*, *Clin. Oncol.*, 1996, **14**, 3056–3061.
- Dancey, J. and Eisenhauer, E. A., *Br. J. Cancer*, 1996, **74**, 327–338.
- Priel, E., Showalter, S. D., Roberts, M., Oroszlan, S. and Blair, D., *J. Virol.*, 1991, **65**, 4137–4141.
- Verma, J. and Indira, K., *Down to Earth*, 1998, **6**, 15–23.
- Ved, D. K., *Amruth*, 1997, **1**, 2–8.
- Ravi Kumar and Ved, D. K., *100 Red-listed Medicinal Plants of Conservation Concern in Southern India*, Foundation for Revitalization of Local Health Traditions, Bangalore, 2000, pp. 261–263.

H. C. HOMBE GOWDA<sup>†</sup>

R. VASUDEVA<sup>†,\*</sup>

GEORGI P. MATHACHEN<sup>†</sup>

R. UMA SHANKER<sup>#</sup>

K. N. GANESHAIAH<sup>‡</sup>

<sup>†</sup>Department of Forest Biology,  
College of Forestry,  
Sirsi 581 401, India

<sup>#</sup>Department of Crop Physiology, and

<sup>‡</sup>Department of Genetics and Plant  
Breeding,

University of Agricultural Sciences,  
GKVK Campus,

Bangalore 560 065, India

For correspondence

\*e-mail: vasukoppa@yahoo.com

## Evolution of *Mycobacterium leprae* towards reduced virulence

Leprosy has been a dreaded disease for at least a few thousand years<sup>1</sup>. After the Dapsone treatment became available in the 1940s (ref. 2) and further, the MDT regime came into practice in the early 1980s (refs 2–4), there has been a substantial reduction in the prevalence of leprosy almost throughout the world<sup>2,3,5,6</sup>.

This is not too surprising given the effectiveness of MDT. But it is not only the incidence that is seen changing. A curious anecdote generally noted by all leprosy clinicians is that the 'face of leprosy' is changing. Not only is the proportion of patients with deformities going down, the textbook leonine faces are much less

infrequently seen now. While an obvious factor can be early detection of cases and treatment, more subtle processes can lead to reduction in virulence of *Mycobacterium leprae*. Evolutionary changes in the virulence of the pathogen can take place over just a few decades and can significantly affect the clinical as well as epide-

miological picture<sup>7</sup>. Here we suggest an evolutionary explanation for the change in the clinical picture of leprosy. We further discuss the hypothesis in the light of available epidemiological data and suggest more testable predictions of the hypothesis.

The different forms of leprosy are at least partially due to differences in the immune state and genetic background of individuals. However, it is also likely that there are variants of *M. leprae* with different virulence. The hypothesis assumes that variants with high virulence are more likely to cause even more severe and infectious forms of leprosy. Due to social stigma and ignorance, the milder cases are less likely to come forward for treatment. The severe cases, on the other hand, will almost certainly undergo treatment. As a result, MDT will select against the more virulent variants. The milder strains would then enjoy a competitive advantage over the virulent ones, and therefore evolution under the influence of MDT would drive *M. leprae* towards reduced virulence.


The time trends available in published literature show that although there is considerable variation in the time trend in different areas, the proportion of lepromatous (LL) or multibacillary (MB) cases is generally going down<sup>2,4,8-12</sup>. Figure 1 shows that out of the ten differential time trends in lepromatous or MB leprosy, seven have a significant negative trend, two do not have any significant trend and only one has a significant upward trend. The clinical picture is therefore compatible with the hypothesis. The downward trends have been interpreted as being clinical and epidemiological effects of the treatment but not as evolutionary effects of the treatment. The reduction in deformities can be the sole effect of early detection and treatment. Increasing awareness can result in greater proportion of milder cases volunteering for treatment and therefore the proportion of Paucibacillary (PB) cases in clinical records can go up. The initial decrease in the percentage of lepromatous cases can be attributed to 'backlog clearance'<sup>12</sup>. These explanations, however, cannot account for the consistent trend seen among the newly detected cases in population surveys over a prolonged time span<sup>2,11</sup>. Specifically, trends in the young-age class also have been consistently negative<sup>2</sup>, suggesting that an evolutionary cause is likely in addition to a clinical one.

The evolutionary hypothesis makes a number of subtle assumptions that need justification and empirical or epidemiological testing. If different variants are partially responsible for the different clinical pictures, it could be shown that the contacts of lepromatous patients are more likely to develop lepromatous type<sup>13</sup> and so on. This question has not been seriously addressed, but an apparent tendency for the clinical picture to mimic the source is seen in some published data<sup>14-16</sup>. The pattern needs to be tested rigorously. The earlier belief that only LL or MB patients are infectious no longer exists, and BB or PB leprosy is also shown to be infectious<sup>17-19</sup>. The clinical course of leprosy is self-curing at times<sup>20,21</sup>. The milder forms are more likely to be self-healing, although lepromatous cases have also shown this phenomenon<sup>21</sup>. The benign self-curing cases are important because they can go undetected and spread the milder variant effectively.

The assumption that milder cases more often go undetected and therefore

untreated, has substantial evidence. A comparison of clinical record and intensive population surveys in southern India reveals this. The proportion of MB cases recorded before the survey was substantially greater than that recorded after the survey<sup>5</sup>, indicating that a large proportion of PB cases did not volunteer for treatment and only intensive surveys could detect them.

What is so peculiar about leprosy? Antimicrobial treatments are available for a number of infectious agents. But there is hardly any evidence of reduced virulence in response to antimicrobial treatment. The social perception of leprosy makes it different from the evolutionary point of view. The difference between the true epidemiological picture and the clinical picture, as apparent in southern India<sup>5</sup>, is due to the social factors that prevent a patient from coming forward for treatment voluntarily, unless the severity of symptoms compel. In most of the places, leprosy patients are not treated in general wards. There are separate leprosy-care units. For a patient,



**Figure 1.** Time trends in the proportion of lepromatous or MB in newly detected cases. Data sets where a consistent survey methodology was used are chosen. Significance of the trend is tested using non-parametric correlation. In the Pune and Chandrapur data, the working definition of MB was changed in the mid-1990s. Therefore the data are terminated at 1993. Interestingly, most of the survey data show significant negative trend, whereas clinical data tend to have non-significant or positive trend.

MB in Taiwan. Survey data (cumulative and new all age and pediatric age patients with leprosy)<sup>2</sup>,  $r = -0.609$ ,  $P < 0.05$ ; MB in Malawi. Clinical data<sup>4</sup>,  $r = 0.686$ ,  $P < 0.01$ ; MB in Uele. Clinical data<sup>8</sup>,  $r = 0.212$ , NS; MB in Taiwan. Survey data<sup>2</sup>,  $r = -0.902$ ,  $P < 0.01$ ; MB in Pune. Clinical data Jogaikar *et al.* (pers. commun),  $r = -0.399$ , NS; MB in Chandrapur. Survey data (pers. commun),  $r = 0.141$ , NS; Lepromatous cases in Tirukoilur<sup>9</sup>,  $r = -0.99$ ,  $P < 0.01$ ; Lepromatous cases in Polambakkam. Survey data<sup>10</sup>,  $r = -1$ ,  $P < 0.05$ ; Lepromatous cases in Brazil<sup>11</sup>,  $r = -0.881$ ,  $P < 0.01$ ; Lepromatous cases in Poigiri<sup>12</sup>,  $r = -0.974$ ,  $P < 0.05$ .

going to a leprosy centre amounts to advertizing the disease. This leads to reluctance that combined with effective drug treatment can result into differential chemotherapy against different strains of the pathogen. The differential treatment would result in a rapid evolution towards loss of virulence. If, on the other hand, the milder and the virulent variants have the same probability of facing drug treatment, the more virulent forms would gain a selective advantage owing to their rapid proliferation in a host body.

It is important to test this hypothesis rigorously in the context of leprosy. The relevance of the hypothesis, however, is much wider. If we accept that the strategies employed in the treatment of patients influence the evolution of virulence of the pathogen in some way, we can think of 'virulence management' of an infectious agent evolving in a host population<sup>7</sup>, that would allow us better long-term health planning.

1. Pannikar, V. K., *Epidemiol. Lepr.*, 1985, **1**, 1-19.
2. Lue, H. C., Chen, J. C., Chao, J. Y., Hsiao, D., Chou, P. and Lih-Shing, W., *Int. J. Lepr.*, 2000, **68**, 57-62.

3. Meima, A., Gupte, M. D., Gerrit, J. O. and Habbema, J. D. F., *Int. J. Lepr. Mycobacterial Dis.*, 1997, **65**, 305-319.
4. Boerrigter, G. and Ponnighaus, J. M., *Lepr. Rev.*, 1993, **64**, 227-235.
5. Gupte, M. D., *Indian J. Lepr.*, 1994, **66**, 19-35.
6. Ponnighaus, J. M., *Dermatoepidemiology*, 1995, **13**, 525-535.
7. Ewald, P., *Evolution of Infectious Disease*, Oxford University Press, Oxford, 1994.
8. Tonglet, R., Pattyn, S. R., Nsansi, B. N., Eeckhout, E. and Deverchin, J., *Eur. J. Epidemiol.*, 1990, **6**, 404-406.
9. Radhakrishnan, S., Christian, M. and Nair, N. G. K., *Indian J. Med. Res.*, 1982, **76**, 18-35.
10. Nair, N. G. K., Radhakrishnan, S., Christian, M., Ramakrishnan, R. and Gopi, P. G., *Indian J. Lepr.*, 1985, **57**, 562-573.
11. Motta, P. C. and Manuel, Z. G., *Int. J. Lepr.*, 1990, **58**, 453-461.
12. Lechat, M. F., in *Study Group on Epidemiology of Leprosy in Relation to Control*, World Health Organization, Geneva, 7-11 November 1983.
13. Gupte, M. D., *ibid.*
14. Bechelli, L. M. *et al.*, *Bull. W.H.O.*, 1973, **48**, 335-344.
15. Dominguez, M. V. *et al.*, *ibid.*, 1980, **58**, 81-83.

16. Fine, P. E. M. *et al.*, *Am. J. Epidemiol.*, 1997, **146**, 91-102.
17. Fine, P. E. M., *Epidemiol. Rev.*, 1982, **4**, 161-187.
18. Chatterjee, B. R., in *A Window on Leprosy, Gandhi Memorial Leprosy*, 1978, pp. 86-395.
19. Halder, A., Mundle, M., Bhadra, U. K. and Saha, B., *Indian J. Lepr.*, 2001, **73**, 11-17.
20. Ekambaram, V. and Sithambaram, M., *Lepr. India*, 1977, **49**, 387-392.
21. Pannikar, V. K. and Jesudasan, K., *ibid.*, 1983, **55**, 712-713.

Received 13 May 2002; accepted 16 September 2002

ANAGHA U. KALE  
SOMEDATTA CHANDA  
MILIND G. WATVE\*

*Department of Microbiology,  
Abasaheb Garware College,  
Karve Road,  
Pune 411 004, India  
\*For correspondence  
e-mail: watve@vsnl.com*

## MEETINGS/SYMPOSIA/SEMINARS

### Symposium on Advances in Polymeric Building Materials

Date: 6-7 March 2003  
Place: Roorkee

The main aim of the symposium will be to establish an efficient communication channel amongst researchers, industries and user agencies on the latest knowledge and expertise related to new alternate construction materials.

Topics include: Composites of natural and synthetic fibres; Wood substitutes; Plastics building products and their standardization; Construction chemicals (sealants, adhesives, water-proofing, concrete admixtures, etc.); New polymeric resins, paints, coatings and finishes; Use of advanced techniques on materials characterization; Plastics and environment.

Contact: B. Singh  
Organizing Secretary  
Symposium on Advances in Polymeric Building Materials  
Central Building Research Institute  
Roorkee 247 667, India  
Tel. 01332-82481 (O)  
01332-70253 (R)  
Fax: 01332-72272, 72543  
E-mail: singhb@zyberway.com

### National Conference on Frontiers in Enzyme Technology (FET)

Date: 15-16 November 2002  
Place: Coimbatore

The central theme of the seminar is Frontiers in Enzyme Technology, which will be discussed under the following topics: Production of enzymes; Isolation and purification of enzymes; Industrial applications of enzymes; Immobilized enzymes; Therapeutic enzymes; drug intermediates; Enzymes as analytical tools, etc.

Contact: Convenor, FET  
Karpagam Arts and Science College  
Pollachi Main Road  
Eachanari (Post)  
Coimbatore 641 021  
Tel. 0422-611146, 611082  
E-mail: kasc@md5.vsnl.net.in